Pacific Biosciences of California (PACB) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Pacific Biosciences of California stock (PACB) is currently trading at $1.39. Pacific Biosciences of California PS ratio (Price-to-Sales) is 2.62. Analyst consensus price target for PACB is $2.43. WallStSmart rates PACB as Sell.
- PACB PE ratio analysis and historical PE chart
- PACB PS ratio (Price-to-Sales) history and trend
- PACB intrinsic value — DCF, Graham Number, EPV models
- PACB stock price prediction 2025 2026 2027 2028 2029 2030
- PACB fair value vs current price
- PACB insider transactions and insider buying
- Is PACB undervalued or overvalued?
- Pacific Biosciences of California financial analysis — revenue, earnings, cash flow
- PACB Piotroski F-Score and Altman Z-Score
- PACB analyst price target and Smart Rating
Pacific Biosciences of California
📊 No data available
Try selecting a different time range
Smart Analysis
Pacific Biosciences of California (PACB) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around peg ratio and return on equity. Significant fundamental concerns warrant caution or avoidance.
Pacific Biosciences of California (PACB) Key Strengths (1)
59.56% held by institutions, strong professional interest
Supporting Valuation Data
Pacific Biosciences of California (PACB) Areas to Watch (7)
PEG ratio is negative or unavailable
Company is destroying shareholder value
Losing money on operations
Very expensive at 74.5x book value
Small-cap company with higher risk but more growth potential
Revenue is fairly priced at 2.62x sales
Solid revenue growth at 13.80% per year
Pacific Biosciences of California (PACB) Detailed Analysis Report
Overall Assessment
This company scores 26/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 8.0/10) while 7 fall into concern territory (avg 2.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are PEG Ratio, Return on Equity, Operating Margin. Some valuation metrics including PEG Ratio (N/A), Price/Sales (2.62), Price/Book (74.53) suggest expensive pricing. Growth concerns include Revenue Growth at 13.80%, which may limit upside. Profitability pressure is visible in Return on Equity at -213.50%, Operating Margin at -134.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -213.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 13.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PACB Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PACB's Price-to-Sales ratio of 2.62x sits near its historical average of 2.71x (43th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 17% below its historical high of 3.17x set in Mar 2026, and 5% above its historical low of 2.51x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~3.2x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Pacific Biosciences of California (PACB) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Pacific Biosciences of California operates as a stable business with moderate growth and solid fundamentals. Revenue reached 160M with 14% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Free cash flow is -25M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 2.30, so expect amplified moves relative to the broader market.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Pacific Biosciences of California.
Bottom Line
Pacific Biosciences of California offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(19 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 8:28:22 AM
About Pacific Biosciences of California(PACB)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to solve genetically complex problems. The company is headquartered in Menlo Park, California.